FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average b	urden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Ahn Inok (Last) (First) (Middle) 9620 MEDICAL CENTER DRIVE				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RXHN] 3. Date of Earliest Transaction (Month/Day/Year) 12/08/2005					JI	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
										Officer (give title below) Other (specify below)					
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year) 05/03/2006					_X_ For	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
ROCKVILLE, MD 20850															
(Ci	ty)	(State)	(Zip)				Table I -	Non-Deriva	tive Securities	Acquired, D	isposed of,	or Benefic	ially Owned		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye		Year) Ex	2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transac Code (Instr. 8)		ction 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) V Amount (D) Price		(Instr.	Transaction(s) (Instr. 3 and 4)			6. 7. Nature Ownership Form: Beneficia Direct (D) or Indirect (I) (Instr. 4)				
			Table			ive Securit		currently v	re not require alid OMB cor of, or Benefic	ntrol number		the lonn	uispiays a		
Title of Derivative	2. Conversion	3. Transaction Date	3A. Deemed Execution Date, if	4.	ction	5. Number	of	6. Date Exer	cisable and	7. Title and of Underlyi			9. Number of Derivative		
	Conversion or Exercise Price of	Date	Execution Date, if	4. Transac Code		5. Number Derivative Acquired (Disposed of	Securities (A) or of (D)	6. Date Exer	cisable and Date	7. Title and	ng		Derivative Securities Beneficially	Ownershi Form of Derivativ	of Indir Benefic Owners
Derivative Security	Conversion or Exercise	Date	Execution Date, if any	4. Transac Code		5. Number Derivative Acquired (Securities (A) or of (D)	6. Date Exer Expiration I	rcisable and Date /Year) Expiration	7. Title and of Underlyi Securities	ng	Derivative Security	Derivative Securities	Ownershi Form of Derivativ Security: Direct (D or Indirect	(Instr. 4
Derivative Security	Conversion or Exercise Price of Derivative	Date (Month/Day/Year)	Execution Date, if any	4. Transac Code (Instr. 8	3)	5. Number Derivative Acquired (Disposed of (Instr. 3, 4	of Securities (A) or of (D) , and 5)	6. Date Exer Expiration I (Month/Day	rcisable and Date /Year) Expiration	7. Title and of Underlyi Securities (Instr. 3 and	Amount or Number	Derivative Security	Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownershi Form of Derivativ Security: Direct (D or Indirect)	of Indir Benefic Owners (Instr. 4

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Ahn Inok 9620 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850	X					

Signatures

/s/ Ted T.H. Jeong as attorney-in-fact for Inok Ahn	05/05/2006
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Original Form 4 reported \$0.25 as the Exercise Price due to clerical error.
- (2) The options vest and become exercisable as to 30% of the options on January 20, 2006; another 30% of the options on January 20, 2007; and the remaining 40% of the options on January 20, 2008.
- (3) The transaction involved an amendment of outstanding options to change the exercise price from \$0.24 to \$0.80, resulting in the deemed cancellation of the original options and the grant of replacement options with the same vesting and exercisability terms as the cancelled options.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.